CGGS Announces Partnership with ALCON
The Chandler Grant Glaucoma Society (CGGS) is pleased to announce Alcon will continue the commitment to an exclusive five-year partnership to fund the distinguished David L. Epstein Clinician-Scientist Research Award. In June 2021, Aerie Pharmaceuticals, Inc, established the partnership. Alcon continued funding the event when they acquired Aerie Pharmaceuticals in 2023.
The CGGS created this award to honor Dr. Epstein, who is widely considered to be one of the most influential leaders in the world of glaucoma and glaucoma research over the past 40 years. The award is a small way to honor his commitment to the scientific understanding and cure of glaucoma through the support of promising clinician-scientists in research environments. As Joel Schuman, MD, past-president, CGGS, once wrote in a tribute to Dr. Epstein, his “greatest legacy is the army of clinician-scientists whom he inspired throughout his years.”
Dr. Epstein was also a co-founder of Aerie Pharmaceuticals, thus making the initial collaboration between CGGS and Aerie a special way to preserve his legacy, while creating a solid bond between the pharmaceutical company and the entire eye care community.
The commitment includes five, $10,000 research grants, to support the work of dedicated researchers by providing funding to the institutions in which the recipients devote themselves in the field of ophthalmology and glaucoma research.
The first of five recipients was selected in January 2022. The award recipient will be formally recognized during the CGGS meeting held in conjunction with the American Glaucoma Society Annual meeting.
The 2023 Call for Applications is closed.
The Call for Applications for the 2024 Research Award begins April 1, 2024 with a deadline of December 16, 2024.
The 2024 Awardee will be announced at the
CGGS Annual meeting, scheduled for March 2025.
“I truly believe that a lifetime of inquisitiveness in one’s clinical laboratory will be a long-lasting source of ultimate satisfaction in one’s career,” said Dr. Epstein. CGGS and Aerie Pharmaceuticals is delighted to keep Dr. Epstein’s dream alive and his desire for ongoing education and research in glaucoma vigorous and productive.
Annual David L. Epstein Clinician-Scientist Research Award
In their continuing commitment to encourage Fellow research, CGGS created the David Epstein Clinician-Scientist Research Award. A research grant of will be awarded to the chosen recipient's institution. The Call for Applications for the Research Award begins April 1, 2023.
This research award honors David L. Epstein, MD who is widely considered to be one of the most influential leaders in the world of glaucoma and glaucoma research over the past 40 years. The award was created to honor his commitment to the scientific understanding and cure of glaucoma through the support of promising clinician-scientists in research environments.
DAVID L. EPSTEIN CLINICIAN-SCIENTIST RESEARCH
2023 Winner to be Announced March 1, 2024
during the CGGS Annual Meeting in Huntington Beach, CA.
The inaugural awards were announced at the annual Chandler-Grant Glaucoma Society
AAO dinner in Chicago, IL on October 19th, 2014.
Since that time, several research grants have been awarded to the following.
l. to r.: Brian Stagg, MD, PhD (2021 awardee) ; Erin Alward Boese, MD (2020 Awardee); Andrew Williams, MD (2022 Awardee) and Joel Schuman, MD, Past President and Board of Director attend the 2023 Annual meeting in Austin, TX